NasdaqGS - Nasdaq Real Time Price USD

Generation Bio Co. (GBIO)

2.9000

-0.1100

(-3.65%)

At close: April 26 at 4:00 PM EDT

2.9500

+0.05

(+1.72%)

After hours: April 26 at 6:56 PM EDT

Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six abstracts highlighting preclinical data from its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms have been accepted for presentation, including one oral presentation, at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking p

GlobeNewswire 4 days ago

GBIO
-3.65%
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET. A live webcast of the presentation will be available on the investor section of the company’s w

GlobeNewswire 24 days ago

GBIO
-3.65%
Generation Bio Co Reports Full Year and Q4 2023 Financial Outcomes

Advancements in Genetic Medicine Platforms Highlighted Amid Financial Review

GuruFocus.com last month

GBIO
-3.65%
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

GBIO
-3.65%
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia - Development of breakthrough immune-quiet DNA for hemophilia A program continues - Cash balance of $264.4 million expected to fund operations into 2H 2027 CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent

GlobeNewswire last month

GBIO
-3.65%
Generation Bio to Present at the 2024 TD Cowen Health Care Conference

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2024 TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 9:10 a.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generati

GlobeNewswire last month

GBIO
-3.65%
Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. last month

GBIO
-3.65%
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 3:45 p.m. PT in San Francisco. A live webcast of the presentation will be available on the investor section of the company’s website

GlobeNewswire 3 months ago

GBIO
-3.65%
Charles Rowland Bought 179% More Shares In Generation Bio

Potential Generation Bio Co. ( NASDAQ:GBIO ) shareholders may wish to note that the Independent Director, Charles...

Simply Wall St. 4 months ago

GBIO
-3.65%
Director Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO)

In a notable insider transaction, Rowland Charles A Jr, a director at Generation Bio Co, has significantly increased his stake in the company.

GuruFocus.com 4 months ago

GBIO
-3.65%
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms

Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continue Strategic reorganization will result in a 40% reduction of workforce Anticipated cost savings to extend cash runway into 2H 2027 CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating ge

GlobeNewswire 4 months ago

GBIO
-3.65%
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system showed highly selective T cell transduction in humanized mouse model, demonstrating in vivo targeting for T cells and potentially for other extrahepatic tissues and cell types - Third quarter 2023 cash balance of $291.0 million expected to fund operations into 2026 CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE N

GlobeNewswire 5 months ago

GBIO
-3.65%
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform

Figure 1 mRNA expression with T cell ctLNP in humanized mouse model Figure 2 Dose response with T cell ctLNP in humanized mouse model Figure 3a Half-life of stealth LNP in NHPs and mice Figure 3b Biodistribution of stealth LNP in NHPs 70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle (ctLNP) platform confirmed in non-human primates, demonstrating prolon

GlobeNewswire 5 months ago

GBIO
-3.65%
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA

NHP IL-6 profile NHP IL-6 levels following IV infusion of mRNA, ceDNA, or iqDNA delivered via LNP at 1 mg/kg – Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tolerability comparable to mRNA – Company is advancing iqDNA in lieu of prior ceDNA constructs across all programs, including its lead program in hemophilia A – Company is extending cash runway gu

GlobeNewswire 6 months ago

GBIO
-3.65%
Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit

CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Tuesday, September 26, 2023 at 9:30 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the com

GlobeNewswire 7 months ago

GBIO
-3.65%
We're Not Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 7 months ago

GBIO
-3.65%
Insider Buyers Lose US$80k As Generation Bio Sheds US$37m

The recent 11% drop in Generation Bio Co.'s ( NASDAQ:GBIO ) stock could come as a blow to insiders who purchased...

Simply Wall St. 8 months ago

GBIO
-3.65%
Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the 2023 Canaccord Healthcare Conference on Thursday, August 10, 2023 at 11:00 a.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com.

GlobeNewswire 8 months ago

GBIO
-3.65%
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of 4.08% and 88.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks 8 months ago

GBIO
-3.65%
Generation Bio Reports Second Quarter 2023 Financial Results

Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2023 financial results. “We continue to make encouraging progress in the development of our cell-targeted lipid nanoparticle (ctLNP) technology, which is a unique, highly s

GlobeNewswire 8 months ago

GBIO
-3.65%

Performance Overview

Return	GBIO	S&P 500
YTD	+75.76%	+6.92%
1-Year	-37.09%	+25.26%
3-Year	-91.77%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Generation Bio Co. (GBIO)

Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference

Generation Bio Co Reports Full Year and Q4 2023 Financial Outcomes

Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Generation Bio to Present at the 2024 TD Cowen Health Care Conference

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Charles Rowland Bought 179% More Shares In Generation Bio

Director Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO)

Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms

Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform

Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA

Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit

We're Not Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn

Insider Buyers Lose US$80k As Generation Bio Sheds US$37m

Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

Generation Bio Reports Second Quarter 2023 Financial Results

Performance Overview